AGFA-GEVAERT NV (AGFB.BR)

BE0003755692 - Common Stock

1.138  +0.01 (+1.25%)

Fundamental Rating

2

Taking everything into account, AGFB scores 2 out of 10 in our fundamental rating. AGFB was compared to 15 industry peers in the Health Care Technology industry. The financial health of AGFB is average, but there are quite some concerns on its profitability. AGFB has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGFB had negative earnings in the past year.
AGFB had a negative operating cash flow in the past year.
In the past 5 years AGFB reported 4 times negative net income.
AGFB had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of AGFB (-4.01%) is worse than 71.43% of its industry peers.
AGFB has a worse Return On Equity (-14.47%) than 78.57% of its industry peers.
Industry RankSector Rank
ROA -4.01%
ROE -14.47%
ROIC N/A
ROA(3y)-6.95%
ROA(5y)0.93%
ROE(3y)-23.67%
ROE(5y)-5.43%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of AGFB has declined.
With a Gross Margin value of 30.71%, AGFB is not doing good in the industry: 78.57% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of AGFB has remained more or less at the same level.
AGFB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.71%
OM growth 3Y-17.71%
OM growth 5Y-24.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5Y-0.57%

More info and screens

4

2. Health

2.1 Basic Checks

AGFB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGFB remains at a similar level compared to 1 year ago.
The number of shares outstanding for AGFB has been reduced compared to 5 years ago.
The debt/assets ratio for AGFB is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 2.18 indicates that AGFB is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.18, AGFB is in line with its industry, outperforming 50.00% of the companies in the same industry.
AGFB has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.21, AGFB is in line with its industry, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 2.18
ROIC/WACCN/A
WACC9.35%

2.3 Liquidity

A Current Ratio of 1.96 indicates that AGFB should not have too much problems paying its short term obligations.
The Current ratio of AGFB (1.96) is better than 71.43% of its industry peers.
AGFB has a Quick Ratio of 1.15. This is a normal value and indicates that AGFB is financially healthy and should not expect problems in meeting its short term obligations.
AGFB has a Quick ratio (1.15) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.15

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.20% over the past year.
Looking at the last year, AGFB shows a very negative growth in Revenue. The Revenue has decreased by -33.65% in the last year.
Measured over the past years, AGFB shows a very negative growth in Revenue. The Revenue has been decreasing by -12.10% on average per year.
EPS 1Y (TTM)79.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.44%
Revenue 1Y (TTM)-33.65%
Revenue growth 3Y-12.37%
Revenue growth 5Y-12.1%
Sales Q2Q%-7.41%

3.2 Future

Based on estimates for the next years, AGFB will show a very strong growth in Earnings Per Share. The EPS will grow by 31.13% on average per year.
The Revenue is expected to grow by 3.40% on average over the next years.
EPS Next Y77.6%
EPS Next 2Y42.96%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue Next Year3.46%
Revenue Next 2Y3.36%
Revenue Next 3Y3.4%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

AGFB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 55.78 indicates a quite expensive valuation of AGFB.
AGFB's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 20.59. AGFB is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 55.78

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AGFB is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.73

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AGFB's earnings are expected to grow with 31.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.96%
EPS Next 3Y31.13%

More info and screens

0

5. Dividend

5.1 Amount

AGFB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGFA-GEVAERT NV

EBR:AGFB (7/26/2024, 7:00:00 PM)

1.138

+0.01 (+1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap176.19M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 55.78
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.01%
ROE -14.47%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 30.71%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.96
Quick Ratio 1.15
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)79.2%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y77.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-33.65%
Revenue growth 3Y-12.37%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y